Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for ...
Contaminated drinking water in Indore caused severe illness and deaths, exposing the silent threat of water-borne diseases ...
The Indore contaminated water crisis, where sewage leaked into drinking water, sickening hundreds and causing deaths, ...
BioArctic AB's (publ) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...
AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity ...
Introduction Globally, half of all 6.2 million deaths in children are caused by acute illnesses which can be prevented if ...
Intravenous (IV) saline drips, often just normal saline (0.9% sodium chloride solution), have become popular in wellness ...
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback